enGene Therapeutics Inc. (ENGN)
Nasdaq: ENGN · Biological Products, (No Diagnostic Substances) · Saint-Laurent, QC · filing with the SEC since 2023
Filings
172 filings since 2017 beside 96 insider forms · Non-accelerated filer and smaller reporting company and emerging growth company · read from EDGAR on Nov 13, 2026Due nextNon-accelerated filer and smaller reporting company and emerging growth company
10-K
Annual report for the fiscal year ending Oct 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Jan 29, 2027
10-Q
Quarterly report for the quarter ending Jan 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by Mar 17, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 104 days after the quarter ended. The proxy statement was last filed May 8, 2026.
Filings a yearinsider forms included
60886159
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 16 times in the last 36 months, the newest Jul 16, 2026.SEC letters: 12 in the last 36 months, the newest Feb 26, 2026.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 12, 2026
8-K items 2.02, 7.01, 8.01, 9.01
Results released; Investor disclosure (Regulation FD); Other event · Current report
Nov 11, 2026
Jul 16, 2026
8-K items 5.02, 7.01, 9.01
Officer or director change; Investor disclosure (Regulation FD) · Current report
Jul 15, 2026
Jun 18, 2026
8-K/A items 2.05, 5.02
Exit or restructuring costs; Officer or director change · Current report, amended
Jun 16, 2026
Jun 15, 2026
8-K items 2.02, 2.05, 5.02, 7.01, 8.01, 9.01
Results released; Exit or restructuring costs; Officer or director change; Investor disclosure (Regulation FD); Other event · Current report
Jun 13, 2026
May 7, 2026
8-K items 5.02, 7.01, 8.01, 9.01
Officer or director change; Investor disclosure (Regulation FD); Other event · Current report
May 5, 2026
Apr 9, 2026
8-K items 5.03, 7.01, 9.01
Charter, bylaw or fiscal-year change; Investor disclosure (Regulation FD) · Current report
Apr 7, 2026
Mar 9, 2026
8-K items 1.01, 1.02, 9.01
Major agreement signed; Major agreement ended · Current report
Jan 21, 2026
8-K items 1.01, 2.03, 3.02, 9.01
Major agreement signed; New debt or obligation taken on; Shares sold without registration · Current report
Jan 20, 2026
40 of 172 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.